Elacestrant Impresses in EMERALD Trial of Breast Cancer

Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer

Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's

The HER2+ Breast Cancer Landscape Continues to Change

Ahmed Rabie on LinkedIn: Close the Care Gap: Recognizing World Cancer Day 2024

EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer

ASCO Breast Cancer Session 2021: Panel Discussion

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Clinical Trials for Metastatic HER2-positive Breast Cancer

Katherine Sanchez MD on X: Breast cancer has had so many big wins this year. Check out our review of elacestrant, the first trial reporting a pill formulation of SERD is effective